title: Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
abstract: OBJECTIVE
  The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer.
  
  
  METHODS
  Thirty-one patients with stage I-III endometrial cancer were recruited for this study. The stage I patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy.
  
  
  RESULTS
  The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31).
  
  
  CONCLUSIONS
  252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range.
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhou
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Tang
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Ke-Wei
authors.initials: KW
authors.lastname: Zhao
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Xiong
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Chen
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Wen-Jing
authors.initials: WJ
authors.lastname: Xu
authors.affiliation: Research Institute of Surgery and Daping Hospital, Cancer Center, Third Military Medical University, Chongqing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Lei
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods*; D002142:Californium / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D011034:Podophyllotoxin / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D002142:Californium; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine